TELA BIO ($TELA) posted quarterly earnings results for Q4 2025 on Tuesday, March 24th. The company reported earnings of -$0.16 per share, beating estimates of -$0.19 by $0.03. The company also reported revenue of $20,870,000, missing estimates of $21,468,348 by $-598,348.
You can see Quiver Quantitative's $TELA stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
TELA BIO Insider Trading Activity
TELA BIO insiders have traded $TELA stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $TELA stock by insiders over the last 6 months:
- HEALTHCARE PARTNERS FUND 2, L.P. EW purchased 3,604,000 shares for an estimated $4,000,440
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
TELA BIO Hedge Fund Activity
We have seen 18 institutional investors add shares of TELA BIO stock to their portfolio, and 19 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ESSEX WOODLANDS MANAGEMENT, INC. added 3,604,000 shares (+87.7%) to their portfolio in Q4 2025, for an estimated $4,252,720
- UBS GROUP AG added 1,283,667 shares (+592.1%) to their portfolio in Q4 2025, for an estimated $1,514,727
- VELAN CAPITAL INVESTMENT MANAGEMENT LP removed 747,410 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $881,943
- PENTWATER CAPITAL MANAGEMENT LP removed 724,856 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $855,330
- PERKINS CAPITAL MANAGEMENT INC added 563,490 shares (+67.6%) to their portfolio in Q4 2025, for an estimated $664,918
- STONEPINE CAPITAL MANAGEMENT, LLC added 196,513 shares (+9.1%) to their portfolio in Q4 2025, for an estimated $231,885
- SILVERARC CAPITAL MANAGEMENT, LLC removed 135,411 shares (-4.9%) from their portfolio in Q4 2025, for an estimated $159,784
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
TELA BIO Government Contracts
We have seen $32,025 of award payments to $TELA over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- PROSTHETICS - MESH: $11,025
- SURGICAL IMPLANTS: $10,500
- OVITEX 1S PERMANENT 25X30: $10,500
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
TELA BIO Analyst Ratings
Wall Street analysts have issued reports on $TELA in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Lake Street issued a "Buy" rating on 12/01/2025
- Canaccord Genuity issued a "Buy" rating on 11/18/2025
- Citizens issued a "Market Outperform" rating on 11/14/2025
To track analyst ratings and price targets for TELA BIO, check out Quiver Quantitative's $TELA forecast page.
TELA BIO Price Targets
Multiple analysts have issued price targets for $TELA recently. We have seen 4 analysts offer price targets for $TELA in the last 6 months, with a median target of $3.5.
Here are some recent targets:
- Frank Takkinen from Lake Street set a target price of $3.0 on 12/01/2025
- Caitlin Cronin from Canaccord Genuity set a target price of $4.0 on 11/18/2025
- Matt O'Brien from Piper Sandler set a target price of $1.25 on 11/14/2025
- David Turkaly from Citizens set a target price of $5.0 on 11/14/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
